{"drugs":["Anidulafungin","Eraxis"],"mono":{"0":{"id":"928515-s-0","title":"Generic Names","mono":"Anidulafungin"},"1":{"id":"928515-s-1","title":"Dosing and Indications","sub":[{"id":"928515-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Candida endophthalmitis:<\/b> alternative therapy, 200 mg IV on day 1, followed by 100 mg IV once daily for at least 4 to 6 weeks<\/li><li><b>Candidemia:<\/b> 200 mg IV on day 1, then 100 mg IV once daily; continue for at least 14 days after the last positive culture<\/li><li><b>Candidiasis, Cardiovascular system infection:<\/b> 200 mg IV on day 1, followed by 100 to 200 mg IV once daily<\/li><li><b>Candidiasis, Osteoarticular infection:<\/b> alternative therapy, 200 mg IV on day 1, then 100 mg IV once daily for at least 2 weeks, followed by fluconazole therapy<\/li><li><b>Candidiasis of the esophagus:<\/b> 100 mg IV on day 1, then 50 mg IV every day for a minimum of 14 days and for at least 7 days following resolution of symptoms (manufacturer dosing)<\/li><li><b>Candidiasis of the esophagus:<\/b> (alternative therapy) 200 mg IV on day 1, followed by 100 mg IV daily for 14 to 21 days (guideline dosing)<\/li><li><b>Candidiasis of the esophagus - HIV infection:<\/b> 100 mg IV on day 1, then 50 mg IV once daily for a minimum of 14 days and for at least 7 days following resolution of symptoms (manufacturer dosing)  OR for a total duration of 14 to 21 days (guideline dosing)<\/li><li><b>Disseminated candidiasis, chronic:<\/b> alternative therapy, 200 mg IV on day 1, then 100 mg IV once daily for 1 to 2 weeks, followed by oral fluconazole therapy when clinically stable<\/li><li><b>Disseminated candidiasis, Intra-abdominal and peritonitis:<\/b> 200 mg IV on day 1, then 100 mg IV once daily; continue for at least 14 days after the last positive culture<\/li><li><b>Empirical antifungal therapy, Suspected candidiasis in non-neutropenic patients:<\/b> primary therapy, 200 mg IV on day 1, followed by 100 mg IV once daily until cultures and\/or serodiagnostic tests are negative<\/li><li><b>HIV infection - Oropharyngeal candidiasis:<\/b> (fluconazole-refractory) 100 mg IV on day 1, then 50 mg IV daily<\/li><li><b>Oropharyngeal candidiasis:<\/b> (alternative therapy) 200 mg IV on day 1, followed by 100 mg IV once daily<\/li><\/ul>"},{"id":"928515-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>safety and efficacy in pediatric patients 16 years of age and younger have not been established<\/li><li><b>Candidemia:<\/b> greater than 16 years old, 200 mg IV on day 1, then 100 mg IV once daily; continue for at least 14 days after the last positive culture<\/li><li><b>Candidiasis of the esophagus:<\/b> greater than 16 years old, 100 mg IV on day 1, then 50 mg IV once daily for a minimum of 14 days and for at least 7 days following resolution of symptoms (manufacturer dosing)<\/li><li><b>Candidiasis of the esophagus - HIV infection:<\/b> greater than 16 years old, 100 mg IV on day 1, then 50 mg IV once daily for a minimum of 14 days and for at least 7 days following resolution of symptoms (manufacturer dosing)<\/li><li><b>Disseminated candidiasis, Intra-abdominal and peritonitis:<\/b> greater than 16 years old, 200 mg IV on day 1, then 100 mg IV once daily; continue for at least 14 days after the last positive culture<\/li><\/ul>"},{"id":"928515-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>hepatic:<\/b> no dosage adjustment necessary<\/li><li><b>renal:<\/b> no dosage adjustment necessary<\/li><li><b>geriatric:<\/b> no dosage adjustment necessary<\/li><\/ul>"},{"id":"928515-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Candidemia<\/li><li>Candidiasis of the esophagus<\/li><li>Candidiasis of the esophagus - HIV infection<\/li><li>Disseminated candidiasis, Intra-abdominal and peritonitis<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Candida endophthalmitis<\/li><li>Candidiasis, Cardiovascular system infection<\/li><li>Candidiasis, Osteoarticular infection<\/li><li>Disseminated candidiasis, chronic<\/li><li>Empirical antifungal therapy, Suspected candidiasis in non-neutropenic patients<\/li><li>HIV infection - Oropharyngeal candidiasis<\/li><li>Oropharyngeal candidiasis<\/li><\/ul>"}]},"3":{"id":"928515-s-3","title":"Contraindications\/Warnings","sub":[{"id":"928515-s-3-9","title":"Contraindications","mono":"hypersensitivity to anidulafungin, any component of the product, or other echinocandins <br\/>"},{"id":"928515-s-3-10","title":"Precautions","mono":"<ul><li>anaphylactic reactions, including shock, have been reported; discontinue use<\/li><li>infusion-related reactions, including rash, urticaria, flushing, pruritus, bronchospasm, dyspnea, and hypotension, have been reported; to reduce occurrence, do not exceed an infusion rate of 1.1 mg\/min<\/li><li>hepatitis, hepatic failure, and significant hepatic dysfunction have been reported; monitoring recommended<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"928515-s-3-11","title":"Pregnancy Category","mono":"<ul><li>B (FDA)<\/li><li>B3 (AUS)<\/li><\/ul>"},{"id":"928515-s-3-12","title":"Breast Feeding","mono":"<ul><li>WHO: Compatible with breastfeeding.  Monitor infant for side effects.<\/li><li>Micromedex: Infant risk cannot be ruled out.<\/li><\/ul>"}]},"5":{"id":"928515-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Endocrine metabolic:<\/b>Hypokalemia (3.1%)<\/li><li><b>Gastrointestinal:<\/b>Diarrhea (3.1%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Deep venous thrombosis (0.8%)<\/li><li><b>Hepatic:<\/b>Abnormal liver function, Hepatic necrosis (less than 2%)<\/li><li><b>Immunologic:<\/b>Anaphylaxis, Hypersensitivity reaction<\/li><li><b>Neurologic:<\/b>Seizure (less than 2%)<\/li><\/ul>"},"6":{"id":"928515-s-6","title":"Drug Name Info","sub":{"0":{"id":"928515-s-6-17","title":"US Trade Names","mono":"Eraxis<br\/>"},"2":{"id":"928515-s-6-19","title":"Class","mono":"<ul><li>Antifungal<\/li><li>Echinocandin<\/li><li>Glucan Synthesis Inhibitor<\/li><\/ul>"},"3":{"id":"928515-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"928515-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"928515-s-7","title":"Mechanism Of Action","mono":"Anidulafungin inhibits the synthesis of beta (1,3)-D-glucan, an essential component of the cell wall of filamentous fungi.<br\/>"},"8":{"id":"928515-s-8","title":"Pharmacokinetics","sub":{"1":{"id":"928515-s-8-24","title":"Distribution","mono":"<ul><li>Protein binding: greater than 99%<\/li><li>Vd: healthy subjects, 30 to 50 L<\/li><li>Vd: immunocompromised pediatric patients, 0.434 L\/kg to 0.537 L\/kg<\/li><li>Vd: infants, 0.9 L\/kg<\/li><li>Vd: neonates, 1.7 L\/kg<\/li><\/ul>"},"2":{"id":"928515-s-8-25","title":"Metabolism","mono":"<ul><li>Hepatic: none observed (not a substrate, inducer, or inhibitor of CYP450)<\/li><li>Undergoes slow chemical degradation at physiologic temperature and pH to a ring-opened peptide (inactive)<\/li><\/ul>"},"3":{"id":"928515-s-8-26","title":"Excretion","mono":"<ul><li>Fecal: healthy adults, 30%.<\/li><li>Renal: healthy adults, less than 1%<\/li><li>Dialyzable: no (hemodialysis)<\/li><li>Total body clearance: patients with fungal infection, 1 L\/hr<\/li><li>Total body clearance: children, 0.0159 L\/kg\/hr to 0.0175 L\/kg\/hr<\/li><li>Total body clearance: infants, 0.015 L\/kg\/hr<\/li><li>Total body clearance: neonates, 0.02 L\/kg\/hr<\/li><\/ul>"},"4":{"id":"928515-s-8-27","title":"Elimination Half Life","mono":"<ul><li>Patients with fungal infections: 26.5 hours<\/li><li>Pediatric patients: 19.9 to 23.1 hours<\/li><\/ul>"}}},"9":{"id":"928515-s-9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>reconstitute with Sterile Water for Injection only; reconstituted drug should be further diluted with D5W or NS only<\/li><li>total infusion volumes for administration: 50 mg dose=65 mL (15 mL of drug and 50 mL of solution); 100 mg dose=130 mL (30 mL of drug and 100 mL of solution); 200 mg dose=260 mL (60 mL of drug and 200 mL of solution)<\/li><li> the diluted solution in the infusion bag may be stored at room temperature up to 25 degrees C (77 degrees F) for up to 48 hours or frozen for at least 72 hours prior to administration<\/li><li>rate of infusion should not exceed 1.1 mg\/min (1.4 mL\/min or 84 mL\/hr when reconstituted and diluted as instructed)<\/li><\/ul>"},"10":{"id":"928515-s-10","title":"Monitoring","mono":"<ul><li>culture and susceptibility tests during treatment, if appropriate<\/li><li>signs and symptoms of Candida fungal infection; improvement is indicative of efficacy<\/li><li>signs and symptoms of worsening hepatic function in patients who develop abnormal liver function tests during therapy<\/li><\/ul>"},"11":{"id":"928515-s-11","title":"How Supplied","mono":"<b>Eraxis<\/b><br\/>Intravenous Powder for Solution: 50 MG, 100 MG<br\/>"},"13":{"id":"928515-s-13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause nausea, diarrhea, vomiting, pyrexia, insomnia, headache, or dyspepsia.<\/li><li>Instruct patient to report signs\/symptoms of new or worsening hepatic dysfunction.<\/li><li>Tell patient to report signs\/symptoms of anaphylactic or hypersensitivity reactions (eg, anaphylactic shock, rash, urticaria, flushing, pruritus, bronchospasm, dyspnea, or hypotension).<\/li><li>Instruct female patients of childbearing potential to notify their physician if they become or plan to become pregnant while receiving treatment.<\/li><li>Instruct female patients to notify their healthcare provider if they are breastfeeding or intend to breastfeed during therapy.<\/li><\/ul>"}}}